FASLG and autoimmune lymphoproliferative syndrome: When tested, unlike PPCR interface FasL mutants (PPCR IFMs), such as E163A, E271A, the described FasL mutations in ALPS patients [such as G277S, A247E, R156G] partially activated cell death of both tumor and Jurkat cells (Fig. 4C, D).